AKR1C1 Interacts with STAT3 to Increase Intracellular Glutathione and Confers Resistance to Oxaliplatin in Colorectal Cancer

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Date 2025 Jan 14

PMID 39807317

Authors

Zhiwen Fu

Tingting Wu

Chen Gao

Lulu Wang

Yu Zhang

Chen Shi

Affiliations

Soon will be listed here.

Abstract

Oxaliplatin (OXA), a platinum-based chemotherapeutic agent, remains a mainstay in first-line treatments for advanced colorectal cancer (CRC). However, the eventual development of OXA resistance represents a significant clinical challenge. In the present study, we demonstrate that the aldo-keto reductase 1C1 (AKR1C1) is overexpressed in CRC cells upon acquisition of OXA resistance, evident in OXA-resistant CRC cell lines. We employed genetic silencing and pharmacological inhibition strategies to establish that suppression of AKR1C1 restores OXA sensitivity. Mechanistically, AKR1C1 interacts with and activates the transcription factor STAT3, which upregulates the glutamate transporter EAAT3, thereby elevating intracellular glutathione levels and conferring OXA resistance. Alantolactone, a potent natural product inhibitor of AKR1C1, effectively reverses this chemoresistance, restricting the growth of OXA-resistant CRC cells both and . Our findings uncover a critical AKR1C1-dependent mechanism behind OXA resistance and propose a promising combinatorial therapeutic strategy to overcome this resistance in CRC.

References

Chang Q, Petrash J . Disruption of aldo-keto reductase genes leads to elevated markers of oxidative stress and inositol auxotrophy in Saccharomyces cerevisiae. Biochim Biophys Acta. 2007; 1783(2):237-45. PMC: 2254213. DOI: 10.1016/j.bbamcr.2007.08.008. View

Mauri G, Gori V, Bonazzina E, Amatu A, Tosi F, Bencardino K . Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treat Rev. 2020; 91:102112. DOI: 10.1016/j.ctrv.2020.102112. View

Wei X, Wei Z, Li Y, Tan Z, Lin C . AKR1C1 Contributes to Cervical Cancer Progression via Regulating TWIST1 Expression. Biochem Genet. 2020; 59(2):516-530. DOI: 10.1007/s10528-020-10014-x. View

Matsunaga T, Suzuki A, Kezuka C, Okumura N, Iguchi K, Inoue I . Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism. Chem Biol Interact. 2016; 256:142-53. DOI: 10.1016/j.cbi.2016.07.008. View

Han D, Yu T, Dong N, Wang B, Sun F, Jiang D . Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019; 38(1):289. PMC: 6612138. DOI: 10.1186/s13046-019-1289-6. View

Sharif S, OConnell M, Yothers G, Lopa S, Wolmark N . FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest. 2008; 26(9):956-63. PMC: 2588473. DOI: 10.1080/07357900802132550. View

Liu X, Zhang Y, Zhuang L, Olszewski K, Gan B . NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulation. Genes Dis. 2021; 8(6):731-745. PMC: 8427322. DOI: 10.1016/j.gendis.2020.11.010. View

Fu Z, Li S, Liu J, Zhang C, Jian C, Wang L . Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer. Front Pharmacol. 2022; 13:847906. PMC: 8965451. DOI: 10.3389/fphar.2022.847906. View

Zhang Y, Li C, Liu X, Wang Y, Zhao R, Yang Y . circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637. EBioMedicine. 2019; 48:277-288. PMC: 6838436. DOI: 10.1016/j.ebiom.2019.09.051. View

10.

Zhang L, Ye B, Chen Z, Chen Z . Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers. Acta Pharm Sin B. 2023; 13(3):982-997. PMC: 10031261. DOI: 10.1016/j.apsb.2022.10.002. View

11.

Mohassab A, Hassan H, Abdelhamid D, Abdel-Aziz M . STAT3 transcription factor as target for anti-cancer therapy. Pharmacol Rep. 2020; 72(5):1101-1124. DOI: 10.1007/s43440-020-00156-5. View

12.

Zhou C, Shen G, Yang F, Duan J, Wu Z, Yang M . Loss of AKR1C1 is a good prognostic factor in advanced NPC cases and increases chemosensitivity to cisplatin in NPC cells. J Cell Mol Med. 2020; 24(11):6438-6447. PMC: 7294127. DOI: 10.1111/jcmm.15291. View

13.

Zhu H, Chang L, Yan F, Hu Y, Zeng C, Zhou T . AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer. Theranostics. 2018; 8(3):676-692. PMC: 5771085. DOI: 10.7150/thno.21463. View

14.

Gargalionis A, Papavassiliou K, Papavassiliou A . Targeting STAT3 Signaling Pathway in Colorectal Cancer. Biomedicines. 2021; 9(8). PMC: 8392110. DOI: 10.3390/biomedicines9081016. View

15.

Liu J, Yuan Y, Cheng Y, Fu D, Chen Z, Wang Y . Copper-Based Metal-Organic Framework Overcomes Cancer Chemoresistance through Systemically Disrupting Dynamically Balanced Cellular Redox Homeostasis. J Am Chem Soc. 2022; 144(11):4799-4809. DOI: 10.1021/jacs.1c11856. View

16.

Lewerenz J, Hewett S, Huang Y, Lambros M, Gout P, Kalivas P . The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2012; 18(5):522-55. PMC: 3545354. DOI: 10.1089/ars.2011.4391. View

17.

Matsumoto R, Tsuda M, Yoshida K, Tanino M, Kimura T, Nishihara H . Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells. Sci Rep. 2016; 6:34625. PMC: 5048132. DOI: 10.1038/srep34625. View

18.

Zhao D, Zhang J, Zhang L, Wu Q, Wang Y, Zhang W . PAFR/Stat3 axis maintains the symbiotic ecosystem between tumor and stroma to facilitate tumor malignancy. Acta Pharm Sin B. 2023; 13(2):694-708. PMC: 9978919. DOI: 10.1016/j.apsb.2022.08.014. View

19.

Chang W, Chang Y, Yang Y, Lin S, Chang P, Hsiao M . AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway. J Exp Clin Cancer Res. 2019; 38(1):245. PMC: 6558898. DOI: 10.1186/s13046-019-1256-2. View

20.

Lae Lae Phoo N, Dejkriengkraikul P, Khaw-On P, Yodkeeree S . Transcriptomic Profiling Reveals AKR1C1 and AKR1C3 Mediate Cisplatin Resistance in Signet Ring Cell Gastric Carcinoma via Autophagic Cell Death. Int J Mol Sci. 2021; 22(22). PMC: 8623627. DOI: 10.3390/ijms222212512. View